oxymark-cd 10*10 tab
unimark - tab - 10*10
montelukast 10mg tablets
bristol laboratories ltd - montelukast sodium - oral tablet - 10mg
hovid imipenem + cilastatin for injection 250mg/250mg
hovid berhad - imipenem monohydrate; cilastatin sodium -
hovid imipenem + cilastatin for injection 500mg/500mg
hovid berhad - imipenem monohydrate; cilastatin sodium -
hovid meropenem for injection 0.5g
hovid berhad - meropenem trihydrate -
hovid meropenem for injection 1g
hovid berhad - meropenem trihyrate -
van-montelukast tablet (chewable)
vanc pharmaceuticals inc - montelukast (montelukast sodium) - tablet (chewable) - 4mg - montelukast (montelukast sodium) 4mg - leukotriene modifiers
van-montelukast tablet (chewable)
vanc pharmaceuticals inc - montelukast (montelukast sodium) - tablet (chewable) - 5mg - montelukast (montelukast sodium) 5mg - leukotriene modifiers
van-montelukast tablet
vanc pharmaceuticals inc - montelukast (montelukast sodium) - tablet - 10mg - montelukast (montelukast sodium) 10mg - leukotriene modifiers
montelukast tablet, chewable
preferred pharmaceuticals inc. - montelukast sodium (unii: u1o3j18sfl) (montelukast - unii:mhm278sd3e) - montelukast 5 mg - montelukast sodium is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older. montelukast sodium is indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 6 years of age and older. montelukast sodium is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 years of age and older. hypersensitivity to any component of this product. pregnancy category b: there are no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, montelukast sodium should be used during pregnancy only if clearly needed. teratogenic effect: no teratogenicity was observed in rats and rabbits at doses approximately 100 and 110 times, respectively, the maximum recommended daily oral dose in adults based on aucs [see nonclinical toxicology (13.2)]. during worldwide marke